CD274 and neoplasm: However, the combination of SETDB1 and PD-L1 inhibition may achieve a superior anti-tumor effect: targeting SETDB1 to directly reduce tumor cell survival and targeting PD-L1 to counteract the negative effects of SETDB1 inhibition and enhance immune function.